Follow this page and receive
notifications about new suppliers
Infliximab API Manufacturers
compare suppliers & get competitive offers
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Follow us
Distributor
Produced in:
Established in: 2005
MOQ: -
Employees: 200+
Portfolio of over 2,000 APIs
Precise quality control
End-to-end global regulatory support
+ 0
All certificates
Producer
Produced in:
Established in: 2019
MOQ: 1 g
Employees: 10+
Focused on pharmaceutical industry
Reasonable price for the customers
Full service from R&D stage to commercial stage
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Infliximab API 170277-31-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Infliximab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Infliximab
- Cas Number:
- 170277-31-3
- DrugBank number:
- DB00065
- Unique Ingredient Identifier:
- B72HH48FLU
About Infliximab
Want to know what Infliximab is used for? Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondyliti, psoriatic arthritis, and plaque psoriasis.
Not sure if this is the exact product you're looking for? Contact the supplier by using the send inquiry button.
Infliximab is a type of Thyreomimetics
Thyreomimetics are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that mimic the actions of the thyroid hormones. These synthetic compounds are designed to interact with the thyroid hormone receptors and elicit similar effects as endogenous thyroid hormones, such as triiodothyronine (T3) and thyroxine (T4).
Thyroid hormones play a crucial role in regulating metabolism, growth, and development in the body. However, individuals with thyroid disorders, such as hypothyroidism or thyroid cancer, may have an impaired production of these hormones. Thyreomimetics offer a targeted therapeutic approach by acting as thyroid hormone agonists, stimulating the receptors and compensating for the deficiency.
These API subcategory drugs exhibit high selectivity and affinity for thyroid hormone receptors, ensuring minimal off-target effects. They are commonly used in the treatment of hypothyroidism, where the thyroid gland fails to produce adequate hormone levels. Thyreomimetics can help normalize metabolic processes and alleviate symptoms like fatigue, weight gain, and depression associated with hypothyroidism.
Furthermore, thyreomimetics are also employed in certain cases of thyroid cancer. By activating thyroid hormone receptors, they suppress the production of thyroid-stimulating hormone (TSH), which can promote tumor growth. This approach aids in the management of thyroid cancer by reducing TSH levels and inhibiting the proliferation of cancer cells.
In conclusion, thyreomimetics are a vital subcategory of pharmaceutical APIs used in the treatment of thyroid disorders. They act as synthetic thyroid hormone analogs, mimicking the effects of endogenous hormones and restoring normal physiological functions. With their targeted action and therapeutic benefits, thyreomimetics play a crucial role in improving the well-being of patients with thyroid-related conditions.
Infliximab (Thyreomimetics), classified under Anti-Thyroid Agents
Anti-thyroid agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of thyroid disorders. These agents are specifically designed to target and inhibit the production or release of thyroid hormones in the body.
One commonly used anti-thyroid agent is propylthiouracil (PTU). PTU works by interfering with the synthesis of thyroid hormones within the thyroid gland, thereby reducing their production. Another widely used anti-thyroid agent is methimazole, which also acts by inhibiting thyroid hormone synthesis. These agents are typically prescribed for individuals with hyperthyroidism, a condition characterized by an overactive thyroid gland that produces an excessive amount of thyroid hormones.
Anti-thyroid agents are available in various forms, including tablets and solutions for oral administration. The dosage and duration of treatment may vary depending on the severity of the condition and individual patient factors.
It's important to note that anti-thyroid agents should be used under the guidance and supervision of a healthcare professional, as they may have potential side effects. These can include allergic reactions, liver toxicity, and blood disorders. Regular monitoring of thyroid function and liver function is typically recommended during treatment.
In summary, anti-thyroid agents are a class of pharmaceutical APIs used in the management of thyroid disorders. They work by inhibiting the production or release of thyroid hormones and are available in different formulations for oral administration. Proper medical guidance is essential for the safe and effective use of these agents.
Infliximab manufacturers | traders | suppliers
We have 4 companies offering Infliximab produced in 4 different countries.
Get in contact with the supplier of your choice:
- LGM Pharma from United States, product country of origin World
- Apino Pharma Co., Ltd. from China, product country of origin China
- Celltrion from South Korea, product country of origin South Korea
- Janssen Pharma from Belgium, product country of origin Netherlands
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
